权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)

怀孕期间停用抗抑郁药后复发的风险（R-DAP 研究）

基本信息

批准号：
10569044
负责人：
Veerle Bergink
金额：
$ 55.2万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-03-02 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10569044
关键词：
Adverse effects Antidepressive Agents Anxiety Disorders Bipolar Disorder Birth Child Conceptions Decision Making Depressive disorder Emotions Endocrine Event Exposure to Fathers Female Fetal Development Fetus General Population Genetic Genetic Predisposition to Disease Genetic study Goals Health Immune Investigation Life Long-Term Effects Mental Depression Mental Health Mental disorders Mood Disorders Moods Mothers Outcome Outpatients Perinatal Pharmaceutical Preparations Physiology Population Postpartum Period Pregnancy Pregnant Women Process Psychiatric therapeutic procedure Relapse Reporting Residual state Resources Risk Risk Factors Risk Reduction Sample Size Sampling Schizophrenia Self-Injurious Behavior Severities Siblings Sleep Deprivation Suicide Suicide attempt Time Woman Work aged antidepressant effect genetic information health of the mother in utero interest maternal depression men offspring perinatal period peripartum depression pharmacologic polygenic risk score population based predictive modeling prenatal exposure relapse risk reproductive secondary outcome tool unborn child

项目摘要

Project Summary Over the past decades, the use of antidepressants (ADs) as first-line treatment for both depressive and anxiety disorders has increased exponentially, with females in their reproductive years using ADs twice as often as men. Prior to conception or during pregnancy, approximately 50% of women on ADs (200,000 pregnant women in the US each year) decide to discontinue their medication. While the wish to avoid in utero AD exposure to the fetus is understandable, discontinuation of medication might lead to relapse, which can have a profound negative impact on the health of mother and child. Unfortunately, general information on relapse risks after AD discontinuation cannot be used during pregnancy and the postpartum period given the enormous changes in physiology and emotion. Further, women discontinue AD prior to or during pregnancy regardless of their mood stability, which has an impact on relapse risk. Only three small studies in highly selected populations have investigated relapse risks during pregnancy and not a single study on AD discontinuation during pregnancy has investigated the relapse risk postpartum. This study will quantify the relapse risk during pregnancy and postpartum after AD discontinuation, for the first time, in a large and representative population sample. We will use the unique Danish national longitudinal registers covering medication use since 1995 in the entire female population giving birth aged 15-49 years (N=1,098,137). With our sample size, we will be able to identify both pregnancy specific and non-pregnancy specific risk factors for relapse and timing to relapse. We will determine to which extent the perinatal period is different in terms of relapse risks after AD discontinuation compared to other periods in a woman’s life. In addition, we will explore if women with high genetic susceptibility for mood-disorders are more vulnerable for relapse after AD discontinuation. In our last aim we will determine the long-term effects (up to 24 years) of maternal relapse during pregnancy and the postpartum period on the offspring. We will conduct a sibling comparison, in which we compare the health outcomes in children exposed to maternal relapse to their siblings not exposed to maternal relapse in the perinatal period. We will explore if polygenic risk scores of the children influence the association between their exposure to maternal relapse and their long-term psychiatric outcome, considering in utero exposure to AD medication.

项目总结